Pyroptosis induction synergized with IDO inhibition of ternary biomedicine for photodynamic activated tumor immunotherapy

Ali Chen; Yang Ni; Wei Zhang; Rongrong Zheng; Rui Yu; Renjing Kong; Yuqing Wang; Hong Cheng; Xiyong Yu; Shiying Li

doi:10.1016/j.cej.2023.147465

ScienceGate Book Chapters

JOURNAL ARTICLE

Pyroptosis induction synergized with IDO inhibition of ternary biomedicine for photodynamic activated tumor immunotherapy

Ali Chen Yang Ni Wei Zhang Rongrong Zheng Rui Yu Renjing Kong Yuqing Wang Hong Cheng Xiyong Yu Shiying Li

Year: 2023 Journal: Chemical Engineering Journal Vol: 478 Pages: 147465-147465 Publisher: Elsevier BV

DOI: 10.1016/j.cej.2023.147465

Get Full-Text PDF Get Analytical Report

Keywords:

Pyroptosis Cancer research Immune system Immunotherapy Tumor microenvironment Cancer immunotherapy Medicine Chemistry Inflammasome Immunology Inflammation

Metrics

Cited By

0.74

FWCI (Field Weighted Citation Impact)

Refs

0.72

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Inflammasome and immune disorders

Life Sciences → Biochemistry, Genetics and Molecular Biology → Molecular Biology

Nanoplatforms for cancer theranostics

Physical Sciences → Engineering → Biomedical Engineering

Heme Oxygenase-1 and Carbon Monoxide

Life Sciences → Biochemistry, Genetics and Molecular Biology → Molecular Biology

Pyroptosis induction synergized with IDO inhibition of ternary biomedicine for photodynamic activated tumor immunotherapy

Metrics

Citation History

Topics

Related Documents

Immunomodulatory‐Photodynamic Nanostimulators for Invoking Pyroptosis to Augment Tumor Immunotherapy

Ferroptosis and Pyroptosis Co‐Activated Nanomodulator for “Cold” Tumor Immunotherapy and Lung Metastasis Inhibition

Self‐Assembled PD‐L1 Downregulator to Boost Photodynamic Activated Tumor Immunotherapy Through CDK5 Inhibition

Cascade Immune Activation of Self‐Delivery Biomedicine for Photodynamic Immunotherapy Against Metastatic Tumor

Photon‐Driven Dye Induction Pyroptosis: An Emerging Anti‐Tumor Immunotherapy Paradigm